Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

Human Psychopharmacology

Volumn 29, Issue 5, 2014, Pages 459-469

  Cabaleiro, Teresa ^a   Ochoa, Dolores ^a   López Rodríguez, Rosario ^a,b   Román, Manuel ^a   Novalbos, Jesús ^a   Ayuso, Carmen ^b,c   Abad Santos, Francisco ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

Author keywords

Adverse effects; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Risperidone

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; PALIPERIDONE; PROLACTIN; RISPERIDONE; AGTR1 PROTEIN, HUMAN; ANGIOTENSIN 1 RECEPTOR; ARYLAMINE ACETYLTRANSFERASE; COMT PROTEIN, HUMAN; NAT2 PROTEIN, HUMAN; NEUROLEPTIC AGENT; PHARMACOLOGICAL BIOMARKER; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHEMOLUMINESCENCE; CONCENTRATION LOSS; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INCIDENCE; INSOMNIA; LEG CRAMP; LIBIDO DISORDER; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POLYDIPSIA; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; TANDEM MASS SPECTROMETRY; XEROSTOMIA; ADOLESCENT; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; GENETIC POLYMORPHISM; GENETICS; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; BIOMARKERS, PHARMACOLOGICAL; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROLACTIN; RECEPTOR, ANGIOTENSIN, TYPE 1; RISPERIDONE; SEX FACTORS; VITAMIN K EPOXIDE REDUCTASES; YOUNG ADULT;

EID: 84922724303     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2420     Document Type: Article

References (52)

1. Almoguera B, Riveiro-Alvarez R, Gomez-Dominguez B, et al. 2010. Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics 11: 1619-1625.
2. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, et al. 2013a. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 23: 627-630.
3. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, et al. 2013b. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics J 13: 197-204.
4. Angelucci F, Bernardini S, Gravina P, et al. 2009. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102 T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. J Alzheimers Dis 17: 203-211.
5. Barter ZE, Tucker GT, Rowland-Yeo K. 2013. Differences in cytochrome P450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 52: 1085-1100.
6. Besnard I, Auclair V, Callery G, et al. 2014. Antipsychotic-drug-induced hyperprolactinemia: Physiopathology, clinical features and guidance. Encéphale 40: 86-94.
7. Cabaleiro T, López-Rodríguez R, Ochoa D, et al. 2013. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol 28: 205-214.
8. Carlsson A. 2006. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39: S10-S14.
9. Cartwright AL, Wilby KJ, Corrigan S, et al. 2013. Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother 47: 350-360.
10. Choong E, Polari A, Kamdem RH, et al . 2013. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol 33: 289-298.
11. Correia CT, Almeida JP, Santos PE, et al. 2010. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 10: 418-430.
12. Cuyàs E, Olano-Martín E, Khymenets O, et al. 2010. Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 11: 257-266.
13. Davies MA, Conley Y, Roth BL. 2011. Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs. Biol Res Nurs 13: 55-60.
14. Fijal BA, Kinon BJ, Kapur S, et al. 2009. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 9: 311-318.
15. Food and Drug Administration. 2011. Icatibant label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022150s000lbl.pdf. Accessed October 2, 2013.
16. Food and Drug Administration. 2012. Risperidone label. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020272s065,020588s053,021444s041lbl.pdf. Accessed October 2, 2013.
17. Furukori N. 2010. Clinical pharmacogenetics in the treatment of schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi Jpn J Psychopharmacol 30: 65-69.
18. Gaedigk A, Simon SD, Pearce RE, et al. 2008. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234-242.
19. Grossman I, Sullivan PF, Walley N, et al. 2008. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 10: 720-729.
20. Houston JP, Kohler J, Bishop JR, et al. 2012. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry 73: 1077-1086.
21. Huang ML, Van Peer A, Woestenborghs R, et al. 1993. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-268.
22. Illi A, Mattila KM, Kampman O, et al. 2003. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J Clin Psychopharmacol 23: 429-434.
23. Jovanović N, Božina N, Lovrić M, et al. 2010. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 66: 1109-1117.
24. Kang CY, Xu XF, Shi ZY, et al. 2010. Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Psychiatry Res 176: 94-95.
25. Karch FE, Lasagna L. 1977. Towards the operational identification of adverse drug reaction. Clin Pharmacol Ther 21: 247-254.
26. Kim B, Choi EY, Kim CY, et al. 2008. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 23: 61-67.
27. Kinon BJ, Gilmore JA, Liu H, et al. 2003. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28: 69-82.
28. Lane HY, Chang YC, Chiu CC, et al. 2002. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 159: 1593-1595.
29. Lane HY, Lee CC, Liu YC, et al. 2005. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6: 139-149.
30. Lencz T, Robinson DG, Xu K, et al. 2006. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in firstepisode schizophrenia patients. Am J Psychiatry 163: 529-531.
31. de Leon J, Susce MT, Pan RM, et al. 2005. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27.
32. de Leon J, Sandson NB, Cozza KL. 2008. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics 49: 258-270.
33. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
34. Llerena A, Berecz R, Peñas-Lledó E, et al. 2013. Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 14: 177-194.
35. López-Rodríguez R, Román M, Novalbos J, et al . 2011. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 31: 555-562.
36. López-Rodríguez R, Cabaleiro T, Ochoa D, et al. 2013. Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics 14: 1203-1214.
37. Mannens G, Huang ML, Meuldermans W, et al. 1993. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 21: 1134-1141.
38. Mas S, Gassò P, Alvarez S, et al. 2012. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 12: 255-259.
39. Molero P, Ortuno F, Zalacain M, et al. 2007. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7: 418-426.
40. Mössner R, Schuhmacher A, Kühn KU, et al. 2009. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 19: 91-94.
41. Novalbos J, López-Rodríguez R, Román M, et al. 2010. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol 30: 504-511.
42. Rothman KJ. 1990. No adjustments are needed for multiple comparisons. Epidemiology 1: 43-46.
43. Saito M, Yasui-Furukori N, Kaneko S. 2005. Clinical pharmacogenetics in the treatment of schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi Jpn J Psychopharmacol 25: 129-135.
44. Savitz DA, Olshan AF. 1998. Describing data requires no adjustment for multiple comparisons: a reply from Savitz and Olshan. Am J Epidemiol 147: 813-814.
45. Schürks M, Zee RY, Buring JE, et al. 2009. Polymorphisms in the reninangiotensin system and migraine in women. Headache 49: 292-299.
46. Strous RD, Lapidus R, Viglin D, et al. 2006. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci Lett 393: 170-173.
47. Swen JJ, Nijenhuis M, de Boer A, et al. 2011. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther 89: 662-673.
48. Tejedor D, Castillo S, Mozas P, et al. 2005. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 51: 1137-1144.
49. Thompson JR. 1998. Invited commentary: Re: "Multiple comparisons and related issues in the interpretation of epidemiologic data". Am J Epidemiol 147: 801-806.
50. Wang L, Fang C, Zhang A, et al. 2008. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 22: 904-909.
51. Xing Q, Qian X, Li H, et al. 2007. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 10: 631-637.
52. Zhao QZ, Liu BC, Zhang J, et al . 2012. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr Genet 22: 298-299.